Products for Research Use Only
RegisterLogin

Terazosin

CAT: 0804-HY-B0371-01Size: 10 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0371-01Size:10 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].
CAS Number
63590-64-7
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Adrenergic Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease; Endocrinology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/terazosin.html
Purity
98.5000
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)CC1)C4OCCC4
Molecular Formula
C19H25N5O4
Molecular Weight
387.43
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362-P403+P233-P405-P501
References & Citations
[1]Michel MC, et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16 (1) :21-8.|[2]Vincent J, et al. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992 Nov;90 (5) :1763-8.|[3]Ju M, et al. Efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy. J Int Med Res. 2020 Apr;48 (4) :300060520904851.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
α adrenergic receptor
Citation 01
Authorea. March 31, 2022.|Eur J Med Chem. 2024 Mar 5:267:116209.|Neurochem Int. 2021 Feb:143:104942.|Research Square Preprint. 2022 Jul.|Cell Prolif. 2025 Mar;58 (3) :e13764.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Res Sq. 2025 Mar 16.

Alternative Products

CatalogName
B3310-250Terazosin
B1365-250Terazosin HCl
TMIJ-0183-01Terazosin-d8
T12815-01(S) -Terazosin
T2680-01Terazosin, Hydrochloride
MBS3612385-01(R)-Terazosin
TRC-T105000-1GTerazosin Hydrochloride
JEA35134(R) -Terazosin
TRC-T105020-1MGTerazosin-md

Popular Products